companies viatris-inc 
Benzinga
FEBRUARY 17, 2023
BMO Capital Markets has downgraded Viatris Inc (NASDAQ: VTRS ) to Market Perform from Outperform and lowered the price estimate to $14 from $16. The analyst writes that Viatris has progressed well with strategic initiatives, but the stock could be rangebound.
Law 360 M&A
NOVEMBER 7, 2022
Health care company Viatris Inc. announced on Monday that it had reached agreements to purchase Oyster Point Pharma and Famy Life Sciences in order to create an ophthalmology franchise, with guidance from Cravath Swaine & Moore LLP.
Benzinga
NOVEMBER 7, 2022
07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. NASDAQ: OYST ), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. Under the terms of the agreement, Viatris will commence a tender offer to purchase all outstanding shares of Oyster Point Pharma for $11.00
Expert insights. Personalized for you.
52 
Let's personalize your content